ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2026
Dose contribution from brachytherapy to the pelvic lymph nodal region during HDR image-guided brachytherapy - a study for rethinking modern volume-based planning.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have evaluated nodal dose using Point-A prescriptions or variable dose rates. However, the impact of volume-based high-dose-rate (HDR) brachytherapy approaches remains less explored. In this study, we aimed to assess the dose contribution to the pelvic lymph nodes with volume-based (HR-CTV) prescription in comparison to point-A-based prescription during HDR brachytherapy in carcinoma cervix. This comparison has not been comprehensively evaluated in earlier literature, especially in the context of elective nodal contouring and HDR brachytherapy. Materials and methods: Thirty patients with carcinoma of the cervix [International Federation of Gynecology and Obstetrics (FIGO) stage IB2 or higher] were included for this retrospective study. Two plans were generated on each brachytherapy scan. The first plan (point-A-based) prescribed a dose of 7 Gy to point-A, while the second plan (HR-CTV-based) prescribed the dose to the HR-CTV. Dose volume histograms (DVH) parameters were compared between both the plans. Results: HR-CTV-based plans registered safer doses to OARs. Both the plans showed noticeable dose contributions to the pelvic lymph node stations, particularly the obturator, internal iliac, and presacral stations, with the highest contribution observed in the obturator group. However, HR-CTV-based plans contributed lower doses to these nodal regions, approximately 1 Gy less to the internal iliac and obturator stations and 2 Gy less to the presacral station compared to point-A-based plans when D50 was considered. Conclusions: HR-CTV-based plans demonstrated recognizable dose contribution to lymph nodes, although lower than the contribution by point-A-based plans. However, this modest difference can be effectively compensated by optimizing the external beam radiotherapy (EBRT) dose while simultaneously maintaining safe organ at risk (OAR) doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.